Gilead Sciences, Inc. (NASDAQ:GILD) Position Reduced by Wintrust Investments LLC

Wintrust Investments LLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 40.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 329 shares of the biopharmaceutical company’s stock after selling 219 shares during the period. Wintrust Investments LLC’s holdings in Gilead Sciences were worth $30,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in GILD. HHM Wealth Advisors LLC raised its holdings in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares in the last quarter. YANKCOM Partnership bought a new stake in Gilead Sciences during the fourth quarter worth approximately $28,000. Decker Retirement Planning Inc. bought a new stake in Gilead Sciences during the fourth quarter worth approximately $29,000. Crews Bank & Trust bought a new stake in Gilead Sciences during the fourth quarter worth approximately $31,000. Finally, Stephens Consulting LLC raised its holdings in Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 260 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 1.7 %

Shares of NASDAQ:GILD opened at $111.44 on Friday. The stock has a market capitalization of $138.78 billion, a PE ratio of 301.19, a P/E/G ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96. The firm has a fifty day moving average price of $101.82 and a 200 day moving average price of $92.71. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.84%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. Gilead Sciences’s dividend payout ratio is 854.05%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 311,285 shares of company stock worth $31,284,910 over the last ninety days. Company insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Bank of America lifted their price target on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Wolfe Research assumed coverage on shares of Gilead Sciences in a research report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price target on the stock. The Goldman Sachs Group lifted their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $80.00 price target on shares of Gilead Sciences in a research report on Wednesday, December 11th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.52.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.